AR037080A1 - Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediarios - Google Patents
Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediariosInfo
- Publication number
- AR037080A1 AR037080A1 ARP010104603A ARP010104603A AR037080A1 AR 037080 A1 AR037080 A1 AR 037080A1 AR P010104603 A ARP010104603 A AR P010104603A AR P010104603 A ARP010104603 A AR P010104603A AR 037080 A1 AR037080 A1 AR 037080A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- group
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0023973A GB0023973D0 (en) | 2000-09-29 | 2000-09-29 | Therapeutically useful compounds |
| GB0107643A GB0107643D0 (en) | 2001-03-27 | 2001-03-27 | Therapeutically useful compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037080A1 true AR037080A1 (es) | 2004-10-20 |
Family
ID=26245081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104603A AR037080A1 (es) | 2000-09-29 | 2001-09-28 | Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediarios |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7157457B2 (enExample) |
| EP (2) | EP1586567A1 (enExample) |
| JP (1) | JP5069392B2 (enExample) |
| KR (1) | KR20030040510A (enExample) |
| CN (1) | CN1478084A (enExample) |
| AR (1) | AR037080A1 (enExample) |
| AT (1) | ATE345331T1 (enExample) |
| AU (1) | AU2001290146A1 (enExample) |
| BR (1) | BR0114321A (enExample) |
| CA (1) | CA2423305A1 (enExample) |
| CZ (1) | CZ20031194A3 (enExample) |
| DE (1) | DE60124576T2 (enExample) |
| ES (1) | ES2275729T3 (enExample) |
| HU (1) | HUP0303107A2 (enExample) |
| IL (1) | IL155092A0 (enExample) |
| MX (1) | MXPA03002813A (enExample) |
| NO (1) | NO20031443L (enExample) |
| NZ (1) | NZ525055A (enExample) |
| PL (1) | PL362984A1 (enExample) |
| WO (1) | WO2002026723A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0207450D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| PT1305329E (pt) | 2000-08-05 | 2007-12-24 | Glaxo Group Ltd | Éster s-fluorometílico do ácido 6.alfa.,9.alfa.-difluoro- 17.alfa.-(2-furanilcarboxil)oxi-11.beta.-hidroxi-16.alfa.-metil- 3-oxo-androsta-1,4-dieno-17-carbotióico como um agente antiinflamatório |
| US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| MY137522A (en) | 2001-04-30 | 2009-02-27 | Glaxo Group Ltd | Novel anti-inflammatory androstane derivatives. |
| TW200400035A (en) | 2002-03-28 | 2004-01-01 | Glaxo Group Ltd | Novel compounds |
| GB0207439D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0207447D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0207449D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0207432D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0207436D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0211759D0 (en) * | 2002-05-22 | 2002-07-03 | Glaxo Group Ltd | Novel compounds |
| GB0212357D0 (en) * | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| US6919356B2 (en) | 2002-09-26 | 2005-07-19 | Bristol Myers Squibb Company | N-substituted heterocyclic amines as modulators of chemokine receptor activity |
| DE60329831D1 (de) * | 2003-06-10 | 2009-12-10 | Biondi Ricardo Miguel | Verwendung einer Verbingung gemäss Formel I zur Herstellung einer pharmazeutischen Zubereitung |
| AR045536A1 (es) | 2003-08-29 | 2005-11-02 | Ranbaxy Lab Ltd | Inhibidores de la fosfodiesterasa tipo -iv |
| IN2014CN03493A (enExample) | 2004-09-08 | 2015-07-03 | Mitsubishi Tanabe Pharma Corp | |
| EP1992628A1 (en) | 2007-05-18 | 2008-11-19 | Glaxo Group Limited | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones |
| US20080207659A1 (en) | 2007-02-15 | 2008-08-28 | Asit Kumar Chakraborti | Inhibitors of phosphodiesterase type 4 |
| EP2132176A1 (en) * | 2007-03-13 | 2009-12-16 | Arete Therapeutics, Inc. | 4-piperidinylurea compounds as soluble epoxide hydrolase inhibitors |
| JP5313881B2 (ja) | 2007-04-04 | 2013-10-09 | 興和株式会社 | テトラヒドロイソキノリン化合物 |
| CA2707555A1 (en) | 2007-12-05 | 2009-06-11 | Astrazeneca Ab | Piperazines as anti-obesity agents |
| US8093248B2 (en) | 2007-12-05 | 2012-01-10 | Astrazeneca Ab (Publ) | Compounds useful for the treatment of conditions associated with weight gain |
| EP2785338A1 (en) | 2011-12-01 | 2014-10-08 | Glaxo Group Limited | Methods of treatment and prevention of eye diseases |
| FR3022142B1 (fr) | 2014-06-16 | 2019-07-12 | Universite Paul Sabatier - Toulouse Iii | Inhibition de la chimiokine ccl7 ou de son recepteur ccr3 pour le traitement et le diagnostic du cancer de la prostate |
| EP3639824A1 (en) | 2014-08-22 | 2020-04-22 | GlaxoSmithKline Intellectual Property Development Limited | Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection |
| EP3570893A1 (en) | 2017-01-17 | 2019-11-27 | GlaxoSmithKline Intellectual Property Development Ltd | Non peptidic heterobivalent molecules for treating inflammatory diseases |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
| CN111269340B (zh) * | 2020-03-31 | 2020-12-29 | 台州学院 | 一种以1-甲烷磺酰哌嗪为配体的螯合树脂及其制备方法和应用 |
| CN120132049B (zh) * | 2025-03-05 | 2025-08-26 | 西南医科大学附属口腔医院 | 茶多酚涂层改性的3d打印掺锶羟基磷灰石复合支架的制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3087763B2 (ja) | 1990-11-30 | 2000-09-11 | 三井化学株式会社 | 新規な複素環式化合物およびそれを含有する医薬組成物 |
| JPH04247074A (ja) * | 1991-02-01 | 1992-09-03 | Yoshitomi Pharmaceut Ind Ltd | ４−モルホリノ安息香酸誘導体の製造法 |
| JPH04270272A (ja) * | 1991-02-25 | 1992-09-25 | Yoshitomi Pharmaceut Ind Ltd | アミノアルキルモルホリン誘導体の製造法 |
| US5753654A (en) * | 1994-05-18 | 1998-05-19 | Nisshin Flour Milling Co., Ltd. | Diaminomethylidene derivatives |
| KR970703301A (ko) * | 1994-05-18 | 1997-07-03 | 쇼오다 오사무 | 신규 디아미노메틸리덴 유도체(novel diamincmethylidene derivative) |
| NZ504436A (en) * | 1997-11-12 | 2001-08-31 | Bayer Ag | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| CN1158256C (zh) * | 1998-11-20 | 2004-07-21 | 霍夫曼-拉罗奇有限公司 | 吡咯烷衍生物-ccr-3受体拮抗剂 |
| EP1156807A4 (en) | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS |
| WO2000035876A1 (en) * | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity |
-
2001
- 2001-09-28 CA CA002423305A patent/CA2423305A1/en not_active Abandoned
- 2001-09-28 NZ NZ525055A patent/NZ525055A/en unknown
- 2001-09-28 US US10/381,871 patent/US7157457B2/en not_active Expired - Lifetime
- 2001-09-28 AU AU2001290146A patent/AU2001290146A1/en not_active Abandoned
- 2001-09-28 HU HU0303107A patent/HUP0303107A2/hu unknown
- 2001-09-28 WO PCT/GB2001/004350 patent/WO2002026723A1/en not_active Ceased
- 2001-09-28 KR KR10-2003-7004593A patent/KR20030040510A/ko not_active Withdrawn
- 2001-09-28 ES ES01970027T patent/ES2275729T3/es not_active Expired - Lifetime
- 2001-09-28 EP EP05076503A patent/EP1586567A1/en not_active Withdrawn
- 2001-09-28 PL PL01362984A patent/PL362984A1/xx not_active Application Discontinuation
- 2001-09-28 CN CNA018196489A patent/CN1478084A/zh active Pending
- 2001-09-28 MX MXPA03002813A patent/MXPA03002813A/es unknown
- 2001-09-28 CZ CZ20031194A patent/CZ20031194A3/cs unknown
- 2001-09-28 DE DE60124576T patent/DE60124576T2/de not_active Expired - Lifetime
- 2001-09-28 AR ARP010104603A patent/AR037080A1/es not_active Application Discontinuation
- 2001-09-28 IL IL15509201A patent/IL155092A0/xx unknown
- 2001-09-28 JP JP2002531107A patent/JP5069392B2/ja not_active Expired - Lifetime
- 2001-09-28 AT AT01970027T patent/ATE345331T1/de not_active IP Right Cessation
- 2001-09-28 EP EP01970027A patent/EP1324991B1/en not_active Expired - Lifetime
- 2001-09-28 BR BR0114321-2A patent/BR0114321A/pt not_active IP Right Cessation
-
2003
- 2003-03-28 NO NO20031443A patent/NO20031443L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004509953A (ja) | 2004-04-02 |
| HUP0303107A2 (hu) | 2004-03-01 |
| ES2275729T3 (es) | 2007-06-16 |
| CN1478084A (zh) | 2004-02-25 |
| ATE345331T1 (de) | 2006-12-15 |
| WO2002026723A1 (en) | 2002-04-04 |
| KR20030040510A (ko) | 2003-05-22 |
| CA2423305A1 (en) | 2002-04-04 |
| DE60124576D1 (de) | 2006-12-28 |
| DE60124576T2 (de) | 2007-06-21 |
| EP1324991B1 (en) | 2006-11-15 |
| EP1586567A1 (en) | 2005-10-19 |
| IL155092A0 (en) | 2003-10-31 |
| AU2001290146A1 (en) | 2002-04-08 |
| EP1324991A1 (en) | 2003-07-09 |
| MXPA03002813A (es) | 2003-10-15 |
| NO20031443L (no) | 2003-05-26 |
| NZ525055A (en) | 2004-09-24 |
| US7157457B2 (en) | 2007-01-02 |
| JP5069392B2 (ja) | 2012-11-07 |
| PL362984A1 (en) | 2004-11-15 |
| BR0114321A (pt) | 2003-07-01 |
| US20040058907A1 (en) | 2004-03-25 |
| CZ20031194A3 (cs) | 2003-08-13 |
| NO20031443D0 (no) | 2003-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037080A1 (es) | Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediarios | |
| AR035205A1 (es) | Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas | |
| PE20250071A1 (es) | Compuesto ciclico que contiene accion inhibidora selectiva en kras por sobre hras y nras | |
| CO5251381A1 (es) | Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
| AR033845A1 (es) | Compuestos de aza y poliaza-naftalenil carboxamidas utiles como inhibidores de la integrasa del vih, composiciones y su uso en la preparacion de medicamentos | |
| AR069412A1 (es) | Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras. | |
| AR065772A1 (es) | Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas. | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| AR035933A1 (es) | Un compuesto derivado de fosfonato nucleosido aciclico, uso del mismo, un proceso para su preparacion y un compuesto de fosfonato. | |
| AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
| AR010560A1 (es) | Compuestos derivados de nonoato donantes de oxido nitrico; composiciones farmaceuticas que los contienen; metodo para la dilatacion local de los vasossanguineos de mamiferos y metodo para matar o inactivar bacterias en la boca de un mamifero | |
| AR002012A1 (es) | Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto. | |
| AR059571A1 (es) | Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas | |
| CO5560559A2 (es) | Formulacion de suspension oral estabilizada | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| NO166129C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydro-9h-pyrido (3,4-b)indoler. | |
| ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
| ES2059391T3 (es) | Derivados de dihidropiridina, su preparacion y su uso. | |
| TR200000727T2 (tr) | 5HT geri alım inhibitörü ve h5-HT1B antagonistinin bir bileşimi. | |
| DK1320526T3 (da) | Farmaceutisk aktive benzsulfonamidderivater som inhibitorer af protein-junkinaser | |
| RU2001118831A (ru) | Макролиды, обладающие противовоспалительной активностью | |
| TR200000725T2 (tr) | Bir monoamin oksidaz inhibitörü ve h5-HT1B antagonistinin bileşimi | |
| AR012443A1 (es) | Nuevas carboxamidas como inhibidores de la agregacion plaquetaria, procedimiento para su preparacion, composiciones farmaceuticas que loscontienen y uso de los mismos en la manufactura de medicamentos | |
| AR030239A1 (es) | Fta lidas substituidas, un procedimiento para su preparacion y composiciones farmaceuticas que contienen las mismas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |